PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr- labeled panitumumab

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 113-120

  Nayak, Tapan K ^a   Garmestani, Kayhan ^a   Milenic, Diane E ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

89Zr; HER1; ImmunoPET; Metastatic colorectal cancer; MRI; Panitumumab; PET

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PANITUMUMAB; PANITUMUMAB ZR 89; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISTANT METASTASIS; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LUNG METASTASIS; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; RECEPTOR BINDING; RECEPTOR BLOCKING; RISK ASSESSMENT; THORAX TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICE; PERITONEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN TRANSPORT; RADIOCHEMISTRY; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; ZIRCONIUM;

EID: 84855385828     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.094169     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol. 2010;36:599-603.
3. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383-1388.
4. Normanno N, De Luca A, Salomon DS, Ciardiello F. Epidermal growth factorrelated peptides as targets for experimental therapy of human colon carcinoma. Cancer Detect Prev. 1998;22:62-67. (Pubitemid 28073343)
5. Ciardiello F, Kim N, Saeki T, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA. 1991;88:7792-7796. (Pubitemid 21915240)
6. Mayer A, TakimotoM, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71:2454-2460. (Pubitemid 23100476)
7. Amador ML, Hidalgo M. Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. Clin Colorectal Cancer. 2004;4:51-62. (Pubitemid 38811512)
8. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810. (Pubitemid 46211358)
9. Hebbar M, Wacrenier A, Desauw C, et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs. 2006;17:855-857.
10. van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010;25:375-385.
11. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991;83:97-104.
12. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positronemitting radionuclides: potentials and challenges. Bioconjug Chem. 2009;20: 825-841.
13. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med. 2009;50:1116-1123.
14. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med. 2010;51:942-950.
15. 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS ONE. 2011;6:e18198.
16. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
17. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol. 1999;26:977-982. (Pubitemid 30047170)
18. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984;142:68-78.
19. Ray GL, Baidoo KE, Wong KJ, et al. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol. 2009;157:1541-1548.
20. Nayak TK, Regino CA, Wong KJ, et al. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab. Eur J Nucl Med Mol Imaging. 2010;37:1368-1376.
21. Milenic DE, Garmestani K, Brady ED, et al. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res. 2008;14:5108-5115.
22. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Dekker; 1982.
23. Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123-131.
24. Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009;115:1544-1554.
25. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
26. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254-1261.